Now, Lupin to Buy German Company

Published: 25th July 2015 03:32 AM  |   Last Updated: 25th July 2015 03:32 AM   |  A+A-

MUMBAI:Pharma firm Lupin Ltd has embarked on an overseas acquisition spree. The country’s third largest drug maker by sales announced its second acquisition in two days and fifth in two years, acquiring Germany-based Temmler Pharma’s specialty product portfolio for an undisclosed sum. The move comes just a day after Lupin pulled off its biggest acquisition - Gavis for $880 million.

The company has entered into a strategic asset purchase agreement with Temmler, part of the Aenova Group, one of the world’s largest pharmaceutical contract manufacturers.

“Temmler’s business has a strong strategic fit with Lupin’s Hormosan business in Germany and enables Lupin to bring an enhanced specialty CNS portfolio to the German market,” said Vinita Gupta, Chief Executive Officer, Lupin.

This will be Lupin’s third acquisition in two years. Last year, it had acquired Laboratories Grin SA, Mexico’s fourth largest drugmaker.

Stay up to date on all the latest Business news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp